ATE408620T1 - Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16 - Google Patents

Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16

Info

Publication number
ATE408620T1
ATE408620T1 AT03747137T AT03747137T ATE408620T1 AT E408620 T1 ATE408620 T1 AT E408620T1 AT 03747137 T AT03747137 T AT 03747137T AT 03747137 T AT03747137 T AT 03747137T AT E408620 T1 ATE408620 T1 AT E408620T1
Authority
AT
Austria
Prior art keywords
amino acid
protein
acid sequence
immunogenic
mutated
Prior art date
Application number
AT03747137T
Other languages
English (en)
Inventor
Daniel Zagury
Buanec Helene Le
Bernard Bizzini
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs filed Critical Neovacs
Application granted granted Critical
Publication of ATE408620T1 publication Critical patent/ATE408620T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03747137T 2002-04-24 2003-04-04 Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16 ATE408620T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0205173A FR2839072A1 (fr) 2002-04-24 2002-04-24 Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation

Publications (1)

Publication Number Publication Date
ATE408620T1 true ATE408620T1 (de) 2008-10-15

Family

ID=28799908

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03747137T ATE408620T1 (de) 2002-04-24 2003-04-04 Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16

Country Status (13)

Country Link
US (1) US7314629B2 (de)
EP (1) EP1509543B1 (de)
JP (1) JP2005532298A (de)
CN (1) CN1656116A (de)
AT (1) ATE408620T1 (de)
AU (1) AU2003249143B2 (de)
BR (1) BR0309491A (de)
CA (1) CA2483819C (de)
DE (1) DE60323634D1 (de)
DK (1) DK1509543T3 (de)
ES (1) ES2312801T3 (de)
FR (1) FR2839072A1 (de)
WO (1) WO2003090667A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8399610B2 (en) * 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
US8452541B2 (en) * 2007-06-18 2013-05-28 Microsoft Corporation Vaccine design methodology
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
JP5146113B2 (ja) * 2008-05-30 2013-02-20 住友電装株式会社 電気接続箱
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (de) * 2009-06-22 2014-04-23 National Health Research Institutes Lipidierte tumorassoziierte antigene und immuntherapiezusammensetzungen
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
CN105177047B (zh) * 2014-08-12 2018-02-02 广东拓谱康生物科技有限公司 携带人乳头瘤病毒16型突变型E7m94抗原基因的重组腺相关病毒载体及其构建方法与应用
CN105177048B (zh) * 2014-08-12 2018-02-02 广东拓谱康生物科技有限公司 携带人乳头瘤病毒16型多点突变型E7mm抗原基因的重组腺相关病毒载体及其构建方法与应用
CN114075293B (zh) * 2020-08-14 2022-11-15 长沙诺盟生物医药有限公司 包含突变的hpv16 e6蛋白的融合蛋白和疫苗组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2038581A1 (en) * 1990-03-20 1991-09-21 Martin Muller Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ES2291039T3 (es) * 1998-09-04 2008-02-16 Sanofi Pasteur Limited Tratamiento del cancer cervical.
JP4799789B2 (ja) * 1999-08-25 2011-10-26 メルク・シャープ・エンド・ドーム・コーポレイション ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
FR2794371B1 (fr) * 1999-10-07 2004-06-18 Biovector Therapeutics Fragments proteiquespolyepitopiques, leur obtention et leurs utilisations notamment en vaccination

Also Published As

Publication number Publication date
DE60323634D1 (de) 2008-10-30
WO2003090667A2 (fr) 2003-11-06
BR0309491A (pt) 2005-02-15
CA2483819C (fr) 2013-01-22
AU2003249143A1 (en) 2003-11-10
FR2839072A1 (fr) 2003-10-31
CA2483819A1 (fr) 2003-11-06
US7314629B2 (en) 2008-01-01
DK1509543T3 (da) 2008-12-15
EP1509543B1 (de) 2008-09-17
ES2312801T3 (es) 2009-03-01
WO2003090667A3 (fr) 2004-04-01
AU2003249143B2 (en) 2008-05-08
CN1656116A (zh) 2005-08-17
JP2005532298A (ja) 2005-10-27
EP1509543A2 (de) 2005-03-02
US20060233820A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
JP2019013251A5 (de)
JP2018510622A5 (de)
ATE408620T1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
EP2383285A3 (de) Peptidsequenzen und Zusammensetzungen
NZ593833A (en) Extended recombinant polypeptides and compositions comprising same
EP2829549A3 (de) Hybrid- und Tandemexpression von neisserschen abgeleiteten Proteinen
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
ATE209216T1 (de) Cyclosporin-derivate mit anti-hiv-wirkung
NO20063026L (no) Antistoffer
JP2015504052A5 (de)
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
JP2010535504A5 (de)
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
RU2005126236A (ru) Фьюжн-белок для подавления цервикального рака
JP2008517998A5 (de)
WO2006116763A3 (en) Lawsonia intracellularis immunological proteins
NZ507983A (en) A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
PE20010316A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS, PEPTIDOS Y PROTEINAS FlgE RELACIONADOS Y SUS USOS
JP2003528614A5 (de)
NO20083576L (no) Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav
JP2004505616A5 (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1509543

Country of ref document: EP